ArticleThe Journal of biological chemistry2026
PIONEER: A periplasmic display platform for synthetic biology-based screening of genetically encoded protein regulators.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Periplasmic display in yeast is a promising but underdeveloped method for screening and studying genetically encoded biomolecules. We present Periplasmic dIsplay Of geNetically Encoded rEgulatoRs (PIONEER), a modular platform that localizes peptides, proteins, and nanobodies to the membrane-proximal periplasmic space of Saccharomycescerevisiae, enabling direct interrogation of membrane protein function. By optimizing secretion signals (ss) and display scaffolds, PIONEER ensures stable ligand retention and robust autocrine signaling. The ability to assess peptide and protein ligand activity through signaling, rather than binding alone, marks a key advance toward function-first screening. Applied to human G protein-coupled receptors, the system enables detection of surface expression, ligand activity profiling, and classification of nanobody regulators, including antagonists and conformational stabilizers. It also distinguishes intrabodies based on their functional effects and chaperone activity. Although demonstrated with G protein-coupled receptors, PIONEER is adaptable to a wide range of membrane and soluble protein targets. As AI-driven design expands the space of candidate ligands and binders, this platform offers a scalable method for linking predicted sequences and their structures to biological function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.